Journal
AUTOPHAGY
Volume 7, Issue 10, Pages 1159-1172Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/auto.7.10.16818
Keywords
endoplasmic reticulum stress; apoptosis; autophagy; sorafenib; hepatocellular carcinoma
Categories
Funding
- National NSFC [N.30801103, N. 81001056]
- National Key Sci-Tech Project [2008ZX10002-019]
- Shanghai Rising-Star Program [09QA1401100, 11QA1401200]
- PhD. Programs Foundation of Ministry of Education of China [200802461028, 20100071120063]
Ask authors/readers for more resources
Sorafenib, a potent multikinase inhibitor, has been recognized as the standard systemic treatment for patients with advanced hepatocellular carcinoma (HCC). However, the direct functional mechanism of tumor lethality mediated by sorafenib remains to be fully characterized, and the precise mechanisms of drug resistance are largely unknown. Here, we showed sorafenib induced both apoptosis and autophagy in human HCC cells through a mechanism that involved endoplasmic reticulum (ER) stress and was independent of the MEK1/2-ERK1/2 pathway. Upregulation of IRE1 signals from sorafenib-induced ER stress was critical for the induction of autophagy. Moreover, autophagy activation alleviated the ER stress-induced cell death. Inhibition of autophagy using either pharmacological inhibitors or essential autophagy gene knockdown enhanced cell death in sorafenib treated HCC cell lines. Critically, the combination of sorafenib with the autophagy inhibitor chloroquine produced more pronounced tumor suppression in HCC both in vivo and in vitro. These findings indicated that both ER stress and autophagy were involved in the cell death evoked by sorafenib in HCC cells. The combination of autophagy modulation and molecular targeted therapy is a promising therapeutic strategy in treatment of HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available